Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Phase III METEOR trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
How can sequential therapy be used in castration-resistant prostate cancer?
Results of KEYNOTE-024 trial of pembrolizumab in NSCLC
The impact of p53 mutation on survival in EGFR-mutated NSCLC patients